Member Info for Zoom0001

Forgot what it looked like!

Wholeheartedly disagree. What’s the point of the caveat if they have no intention of exploiting the business channel? I think home testing is definitely where it’s at for them, but if Avacta are struggling to sell, Medusa could be selling now & their not.

They have been supplying their protein test to businesses for the best part of a year. Not sure I would describe it as not their thing.

Have non exclusive rights for supply to business. Any ideas on what they might be waiting for? It leads me to believe there isn’t any supply for them at the moment, hence we only have one distributor at this stage. There must be a good volume of tests earmarked for something or this situation has been completely mismanaged, which I don’t believe to be the case.

Almost like AS can predict the future. He wanted our LFT to perform bang on the infectious sweet spot. I remember his explanation during the first presentation.

Cheers.

Sorry, email lincspoacher. Could you share the Twitter link to the e-mail?

You mentioned posting the letter on Twitter. Could you post the link?

https://www.londonstockexchange.com/news-article/UJO/west-newton-b-1z-update/15066762

https://www.londonstockexchange.com/news-article/RBD/west-newton-operations-update/15066814

46.5k cases & 96 recorded deaths.

Definitely no requirement for super sensitive tests going forwards.

Medusa have exclusive direct to consumer rights. Something’s not adding up.

Global, exclusive, direct-to-consumer sales and marketing agreement for COVID-19 self-testing

I was actually genuinely interested in a response.

& you know this how exactly?

We really are scraping the barrel if relying on positivity from Deeks.

I thought it was an interesting observation Parkers. Thanks for sharing.

Not sure why they would reference government equipment & capacity in the same presentation if they weren’t pursuing the government sales channel.

Is this why Boris is so confident? What an absolute tool. Israel’s always been the benchmark for me.

In Israel there are disturbing suggestions the Covid vaccine may be losing its efficacy in older people, with Hebrew University in Jerusalem reporting that 90pc of confirmed cases in the over-50s were people who had been fully vaccinated.

I think $41 billions a typo, $41 million deal.

Personally, I think it’s a bit premature to suggest no confidence in Avacta’s management. I’ve always maintained AS knows exactly what he’s doing here. I could be wrong of course. Guess we’ll find out soon enough.